U.S. Software Stock News

NasdaqCM:INVZ
NasdaqCM:INVZElectronic

A Look At Innoviz Technologies (INVZ) Valuation After InnovizThree LiDAR And NVIDIA Edge Processing Reveal

Innoviz Technologies (INVZ) has drawn fresh attention after unveiling InnovizThree, a long range colored LiDAR with integrated RGB camera, alongside an edge processing tie up with NVIDIA Jetson Orin Nano, which was showcased at CES 2026. See our latest analysis for Innoviz Technologies. The recent CES 2026 product unveilings and partnerships have arrived after a mixed stretch for the stock, with a 7 day share price return of 33.63% and a 90 day share price return decline of 45.45%, while the...
NYSE:LNN
NYSE:LNNMachinery

Lindsay (LNN) Heads Into Q1 2026 With 10.9% Margin And 11.8% EPS Growth

Lindsay (LNN) opened its Q1 2026 reporting window with recent quarterly revenue ranging from US$153.6 million to US$187.1 million over fiscal 2025 and basic EPS between US$1.00 and US$2.45, culminating in trailing twelve month EPS of US$6.82 on revenue of US$676.4 million. Over the past five reported quarters, revenue has moved between US$139.2 million and US$187.1 million while quarterly EPS has ranged from US$1.17 to US$2.45. This gives investors a clear view of how earnings track alongside...
NYSE:UMH
NYSE:UMHResidential REITs

Is UMH Properties (UMH) Attractively Priced After Mixed Multi Year Share Returns

If you are wondering whether UMH Properties is attractively priced or not, this article walks through the key numbers so you can judge the value for yourself. The share price recently closed at US$16.08, with returns of 1.1% over the last week, 5.2% over the last month, 1.1% year to date, 8.9% over three years, and 34.2% over five years, while the 1 year return sits at a 7.0% decline. Recent coverage has focused on UMH Properties' position within the real estate sector and how investors are...
NasdaqGS:ANGO
NasdaqGS:ANGOMedical Equipment

Assessing AngioDynamics (ANGO) Valuation After Raised Guidance And Med Tech Momentum

AngioDynamics (ANGO) is back on investors’ radar after its Med Tech platforms helped deliver stronger quarterly results, prompting management to raise full year revenue and profitability guidance while outlining an upcoming CEO transition. See our latest analysis for AngioDynamics. Even with the raised guidance and progress in Med Tech platforms, AngioDynamics’ 7 day share price return of 21.73% and 30 day share price return of 23.63% suggest recent momentum has faded, aligning with a 1 year...
NYSE:VFC
NYSE:VFCLuxury

January 2026's Trio of Stocks That May Be Trading Below Estimated Value

As the U.S. stock market experiences a surge, with the S&P 500 reaching new all-time highs and major indexes poised for weekly gains, investors are keenly observing opportunities amidst mixed economic signals like a falling unemployment rate. In this environment of fluctuating indices and evolving economic policies, identifying stocks that may be trading below their estimated value could offer potential avenues for growth and diversification.
NYSE:LOB
NYSE:LOBBanks

Top Growth Companies With Significant Insider Ownership

As the U.S. stock market experiences a surge, with the S&P 500 reaching new all-time highs and major indexes poised for weekly gains, investors are keenly observing growth companies that combine robust performance with substantial insider ownership. In this thriving economic landscape, stocks with high insider ownership can be particularly appealing as they often indicate strong confidence from those who know the company best, aligning their interests with those of external shareholders.
NYSEAM:PLX
NYSEAM:PLXBiotechs

Baozun And 2 Other Promising Penny Stocks

As the U.S. stock market experiences a surge, with major indexes like the S&P 500 reaching new all-time highs, investors are increasingly looking for opportunities beyond traditional large-cap stocks. Despite its somewhat outdated connotation, the term "penny stock" continues to highlight investment potential in smaller or newer companies that may offer significant returns when backed by strong financials. In this article, we explore three penny stocks that demonstrate balance sheet...
NasdaqCM:BHRB
NasdaqCM:BHRBBanks

Undiscovered Gems in the US Market for January 2026

As the U.S. stock market continues to soar, with the S&P 500 reaching new all-time highs following a drop in unemployment rates, investors are keenly observing opportunities within the small-cap sector. In this dynamic environment, identifying promising stocks requires a focus on companies that can navigate economic shifts and capitalize on emerging trends.
NYSE:AZZ
NYSE:AZZBuilding

AZZ (AZZ) Net Margin Surge Tests Bearish Earnings Decline Narrative Ahead Of Q3 2026

AZZ (AZZ) has put up a busy run of quarters ahead of its Q3 2026 report, with Q3 fiscal revenue at US$425.7 million and basic EPS of US$1.37, sitting alongside trailing 12 month revenue of about US$1.6 billion and EPS of US$10.73. Over recent periods the company has seen quarterly revenue move from US$403.7 million in Q3 2025 to US$351.9 million in Q4 2025, then into the US$422.0 million to US$425.7 million range in Q1 to Q3 2026, while basic EPS has ranged from US$0.68 in Q4 2025 to US$5.71...
NYSE:UDR
NYSE:UDRResidential REITs

Is UDR (UDR) Offering A Valuation Opportunity After Mixed Share Price Performance?

If you are wondering whether UDR is priced attractively today, this article walks through what the current numbers suggest about the stock's value. UDR recently closed at US$37.32, with returns of 1.7% over the last week, 6.9% over the last month, 1.7% year to date, and a 5.4% decline over the past year. This gives a mixed picture of recent performance. Recent coverage around UDR has focused on how investors are reassessing listed residential real estate, with pricing and capital allocation...
NasdaqCM:ARBE
NasdaqCM:ARBEElectronic

Arbe Robotics (ARBE) Is Up 7.6% After Unveiling NVIDIA‑Powered AI Radar Platform for Hands‑Off Driving

Arbe Robotics recently announced at CES 2026 that it is combining its automotive-grade ultra‑HD radar with NVIDIA’s accelerated computing to create an AI-based perception platform designed for hands-off, eyes-off driving, featuring over 20,000 detections per frame and more than 300 meters of range in varied weather conditions. A distinctive aspect of this development is how the dense radar point cloud, processed on NVIDIA’s in-vehicle computing, is being used to build AI-based occupancy...
NasdaqCM:XPEL
NasdaqCM:XPELAuto Components

Assessing XPEL (XPEL) Valuation After Q3 Revenue Beat And Margin Expansion Plans

Q3 revenue surprise puts XPEL (XPEL) back in focus Recent attention on XPEL (XPEL) stems from its Q3 results, where revenue growth surpassed expectations while earnings per share came in below forecasts. This has prompted investors to reassess the trade off between sales momentum and profitability. See our latest analysis for XPEL. At a share price of $54.63, XPEL has climbed sharply in recent months, with a 90 day share price return of 61.18% and a 1 year total shareholder return of 39.35%...
NYSE:TGLS
NYSE:TGLSBuilding

Tecnoglass (TGLS) Valuation Check After Soft EBITDA Guidance And Industry Weakness Concerns

Tecnoglass (TGLS) shares fell 5.5% after the company issued full-year EBITDA guidance that investors viewed as weak. At the same time, competitor Apogee Enterprises cut its outlook, reinforcing concerns about demand and cost pressures. See our latest analysis for Tecnoglass. At a share price of $51.23, Tecnoglass has a 1-day share price return of 6.86%, but a 90-day share price return decline of 17.46% and a 1-year total shareholder return loss of 30.55%, suggesting momentum has been fading...
NYSE:KRMN
NYSE:KRMNAerospace & Defense

Has Karman Holdings (KRMN) Run Too Far After NYSE Listing And Rapid Share Price Surge?

For investors wondering whether Karman Holdings at around US$101.28 represents an opportunity or is already fully valued, this article walks through what the numbers may indicate about the stock. The share price has been active recently, with returns of 38.4% over the past 7 days, 58.9% over the past 30 days and 31.8% year to date. These movements can influence how you think about potential upside and risk. Recent coverage of Karman Holdings has focused on its listing on the NYSE and growing...
NasdaqGS:ALLT
NasdaqGS:ALLTSoftware

Assessing Allot (ALLT) Valuation As SECaaS ARR Growth Reshapes Its Long‑Term Outlook

Allot (ALLT) is back in focus after reports that its Cybersecurity as a Service business delivered about 60% year over year growth in annual recurring revenue in the third quarter of 2025. See our latest analysis for Allot. That SECaaS momentum comes alongside a $10.86 share price, a 7 day share price return of 10.48% and a 1 year total shareholder return of 50.21%, hinting at building momentum despite a 5.57% 1 day pullback. If Allot’s recent move has caught your eye, it could be a good...
NasdaqGS:DHC
NasdaqGS:DHCHealth Care REITs

A Look At Diversified Healthcare Trust (DHC) Valuation After Its Portfolio Sales And Debt Repayment Reset

Diversified Healthcare Trust (DHC) has set out a fresh course with three linked moves: large non core property sales, full repayment of its 2026 notes, and a broad reset of senior housing operations. See our latest analysis for Diversified Healthcare Trust. Those asset sales, debt repayment and senior housing changes arrive after a sharp shift in investor sentiment, with the share price at US$5.40 and a 90 day share price return of 33.33%, alongside a very large 3 year total shareholder...
NasdaqGM:OCS
NasdaqGM:OCSPharmaceuticals

Assessing Oculis Holding (OCS) Valuation After Privosegtor’s FDA Breakthrough Therapy Designation

Oculis Holding (NasdaqGM:OCS) is back on investor radars after its neuroprotective candidate Privosegtor received FDA breakthrough therapy designation for optic neuritis, supported by Phase 2 ACUITY data and advancement into registrational PIONEER trials. See our latest analysis for Oculis Holding. The FDA breakthrough therapy news has arrived alongside a 10.3% 7 day share price return and a 10.2% year to date share price return, while the 1 year total shareholder return of 17.8% and very...
NasdaqGM:LFMD
NasdaqGM:LFMDHealthcare Services

LifeMD (LFMD) Is Up 17.3% After Expanding Telehealth Access To Wegovy Oral Pill – What’s Changed?

In early January 2026, LifeMD announced it is now offering Novo Nordisk’s newly FDA-approved Wegovy (semaglutide) pill through its nationwide telehealth platform, expanding virtual access to an oral GLP-1 option for chronic weight management and cardiovascular health at cash-pay prices starting from US$149 per month for eligible patients. This move deepens LifeMD’s collaboration with Novo Nordisk and positions the company more firmly in the fast-growing obesity care segment by pairing...